INSMED INC Research and Development Expense
INSMED INC (INSM) reported Research and Development Expense of $210.03 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-06
- INSMED INC research and development expense for the quarter ending 2026-06-30 was $210.03M, a 18.54% increase year-over-year.
- INSMED INC research and development expense for the quarter ending 2026-03-31 was $209.49M, a 37.30% increase year-over-year.
- INSMED INC research and development expense for the quarter ending 2025-12-31 was $254.91M, a 41.83% increase year-over-year.
- INSMED INC research and development expense for the quarter ending 2025-09-30 was $186.41M, a 23.61% increase year-over-year.
- INSMED INC research and development expense for fiscal 2025 was $771.09M, a 28.87% increase from fiscal 2024.
- INSMED INC research and development expense for fiscal 2024 was $598.37M, a 4.79% increase from fiscal 2023.
- INSMED INC research and development expense for fiscal 2023 was $571.01M, a 43.64% increase from fiscal 2022.
- INSMED INC research and development expense for fiscal 2022 was $397.52M, a 45.75% increase from fiscal 2021.
| Period end | Research and Development Expense 3 month | Research and Development Expense 3 month as first filed | Research and Development Expense 6 month | Research and Development Expense 6 month as first filed | Research and Development Expense 9 month | Research and Development Expense 9 month as first filed | Research and Development Expense 12 month | Research and Development Expense 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $210.03M 10-Q · filed 2026-08-06 | $419.52M 10-Q · filed 2026-08-06 | $674.43M derived: sum of 3 quarters · filed 2026-08-06 | $860.85M derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2026-03-31 | $209.49M 10-Q · filed 2026-05-07 | $464.40M derived: sum of 2 quarters · filed 2026-05-07 | $650.81M derived: sum of 3 quarters · filed 2026-05-07 | $828.00M derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2025-12-31 | $254.91M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | $441.33M derived: sum of 2 quarters · filed 2026-02-19 | $618.52M derived: sum of 3 quarters · filed 2026-08-06 | $771.09M 10-K · filed 2026-02-19 | ||||
| 2025-09-30 | $186.41M 10-Q · filed 2025-10-30 | $363.61M derived: sum of 2 quarters · filed 2026-08-06 | $516.18M 10-Q · filed 2025-10-30 | $695.91M derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2025-06-30 | $177.19M 10-Q · filed 2026-08-06 | $329.77M 10-Q · filed 2026-08-06 | $509.49M derived: sum of 3 quarters · filed 2026-08-06 | $660.30M derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2025-03-31 | $152.58M 10-Q · filed 2026-05-07 | $332.30M derived: sum of 2 quarters · filed 2026-05-07 | $483.11M derived: sum of 3 quarters · filed 2026-05-07 | $629.86M derived: sum of 4 quarters · filed 2026-05-07 | ||||
| 2024-12-31 | $179.73M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | $330.54M derived: sum of 2 quarters · filed 2026-02-19 | $477.28M derived: sum of 3 quarters · filed 2026-02-19 | $598.37M 10-K · filed 2026-02-19 | ||||
| 2024-09-30 | $150.81M 10-Q · filed 2025-10-30 | $297.56M derived: sum of 2 quarters · filed 2025-10-30 | $418.64M 10-Q · filed 2025-10-30 | $555.67M derived: sum of 4 quarters · filed 2026-02-19 | ||||
| 2024-06-30 | $146.75M 10-Q · filed 2025-08-07 | $267.83M 10-Q · filed 2025-08-07 | $404.86M derived: sum of 3 quarters · filed 2026-02-19 | $514.01M derived: sum of 4 quarters · filed 2026-02-19 | ||||
| 2024-03-31 | $121.08M 10-Q · filed 2025-05-08 | $258.11M derived: sum of 2 quarters · filed 2026-02-19 | $367.26M derived: sum of 3 quarters · filed 2026-02-19 | $564.23M derived: sum of 4 quarters · filed 2026-02-19 | ||||
| 2023-12-31 | $137.03M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | $246.18M derived: sum of 2 quarters · filed 2026-02-19 | $443.15M derived: sum of 3 quarters · filed 2026-02-19 | $571.01M 10-K · filed 2026-02-19 | ||||
| 2023-09-30 | $109.15M 10-Q · filed 2024-10-31 | $306.12M derived: sum of 2 quarters · filed 2024-10-31 | $433.98M 10-Q · filed 2024-10-31 | $558.75M derived: sum of 4 quarters · filed 2025-02-20 | ||||
| 2023-06-30 | $196.97M 10-Q · filed 2024-08-08 | $324.83M 10-Q · filed 2024-08-08 | $449.60M derived: sum of 3 quarters · filed 2025-02-20 | $549.47M derived: sum of 4 quarters · filed 2025-02-20 | ||||
| 2023-03-31 | $127.86M 10-Q · filed 2024-05-09 | $252.63M derived: sum of 2 quarters · filed 2025-02-20 | $352.50M derived: sum of 3 quarters · filed 2025-02-20 | $441.03M derived: sum of 4 quarters · filed 2025-02-20 | ||||
| 2022-12-31 | $124.76M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-20 | $224.63M derived: sum of 2 quarters · filed 2025-02-20 | $313.16M derived: sum of 3 quarters · filed 2025-02-20 | $397.52M 10-K · filed 2025-02-20 | ||||
| 2022-09-30 | $99.87M 10-Q · filed 2023-10-26 | $188.40M derived: sum of 2 quarters · filed 2023-10-26 | $272.75M 10-Q · filed 2023-10-26 | $349.11M derived: sum of 4 quarters · filed 2024-02-22 | ||||
| 2022-06-30 | $88.53M 10-Q · filed 2023-08-03 | $172.88M 10-Q · filed 2023-08-03 | $249.24M derived: sum of 3 quarters · filed 2024-02-22 | $319.58M derived: sum of 4 quarters · filed 2024-02-22 | ||||
| 2022-03-31 | $84.36M 10-Q · filed 2023-05-04 | $160.71M derived: sum of 2 quarters · filed 2024-02-22 | $231.06M derived: sum of 3 quarters · filed 2024-02-22 | $295.71M derived: sum of 4 quarters · filed 2024-02-22 | ||||
| 2021-12-31 | $76.35M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-22 | $146.70M derived: sum of 2 quarters · filed 2024-02-22 | $211.35M derived: sum of 3 quarters · filed 2024-02-22 | $272.74M 10-K · filed 2024-02-22 | ||||
| 2021-09-30 | $70.35M 10-Q · filed 2022-10-27 | $135.00M derived: sum of 2 quarters · filed 2022-10-27 | $196.39M 10-Q · filed 2022-10-27 | $264.21M derived: sum of 4 quarters · filed 2023-02-23 | ||||
| 2021-06-30 | $64.66M 10-Q · filed 2022-08-04 | $126.05M 10-Q · filed 2022-08-04 | $193.86M derived: sum of 3 quarters · filed 2023-02-23 | $235.27M derived: sum of 4 quarters · filed 2023-02-23 | ||||
| 2021-03-31 | $61.39M 10-Q · filed 2022-05-05 | $129.20M derived: sum of 2 quarters · filed 2023-02-23 | $170.62M derived: sum of 3 quarters · filed 2023-02-23 | $206.36M derived: sum of 4 quarters · filed 2023-02-23 | ||||
| 2020-12-31 | $67.81M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-23 | $109.22M derived: sum of 2 quarters · filed 2023-02-23 | $144.97M derived: sum of 3 quarters · filed 2023-02-23 | $181.16M 10-K · filed 2023-02-23 | ||||
| 2020-09-30 | $41.41M 10-Q · filed 2021-10-28 | $77.16M derived: sum of 2 quarters · filed 2021-10-28 | $113.34M 10-Q · filed 2021-10-28 | $145.97M derived: sum of 4 quarters · filed 2022-02-17 | ||||
| 2020-06-30 | $35.75M 10-Q · filed 2021-08-05 | $71.93M 10-Q · filed 2021-08-05 | $104.56M derived: sum of 3 quarters · filed 2022-02-17 | $138.90M derived: sum of 4 quarters · filed 2022-02-17 | ||||
| 2020-03-31 | $36.18M 10-Q · filed 2021-05-06 | $68.81M derived: sum of 2 quarters · filed 2022-02-17 | $103.15M derived: sum of 3 quarters · filed 2022-02-17 | $136.69M derived: sum of 4 quarters · filed 2022-02-17 | ||||
| 2019-12-31 | $32.63M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-17 | $66.97M derived: sum of 2 quarters · filed 2022-02-17 | $100.51M derived: sum of 3 quarters · filed 2022-02-17 | $131.71M 10-K · filed 2022-02-17 | ||||
| 2019-09-30 | $34.34M 10-Q · filed 2020-10-29 | $67.88M derived: sum of 2 quarters · filed 2020-10-29 | $99.08M 10-Q · filed 2020-10-29 | $139.01M derived: sum of 4 quarters · filed 2021-02-25 | ||||
| 2019-06-30 | $33.54M 10-Q · filed 2020-08-06 | $64.74M 10-Q · filed 2020-08-06 | $104.67M derived: sum of 3 quarters · filed 2021-02-25 | $144.20M derived: sum of 4 quarters · filed 2021-02-25 | ||||
| 2019-03-31 | $31.20M 10-Q · filed 2020-04-30 | $71.13M derived: sum of 2 quarters · filed 2021-02-25 | $110.67M derived: sum of 3 quarters · filed 2021-02-25 | $146.39M derived: sum of 4 quarters · filed 2021-02-25 | ||||
| 2018-12-31 | $39.92M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25 | $79.46M derived: sum of 2 quarters · filed 2021-02-25 | $115.19M derived: sum of 3 quarters · filed 2021-02-25 | $145.28M 10-K · filed 2021-02-25 | ||||
| 2018-09-30 | $39.54M 10-Q · filed 2019-10-30 | $75.26M derived: sum of 2 quarters · filed 2019-10-30 | $105.36M 10-Q · filed 2019-10-30 | $139.31M derived: sum of 4 quarters · filed 2020-02-25 | ||||
| 2018-06-30 | $35.72M 10-Q · filed 2019-08-01 | $65.82M 10-Q · filed 2019-08-01 | $99.77M derived: sum of 3 quarters · filed 2020-02-25 | $126.44M derived: sum of 4 quarters · filed 2020-02-25 | ||||
| 2018-03-31 | $30.10M 10-Q · filed 2019-05-07 | $64.05M derived: sum of 2 quarters · filed 2020-02-25 | $90.72M derived: sum of 3 quarters · filed 2020-02-25 | $117.59M derived: sum of 4 quarters · filed 2020-02-25 | ||||
| 2017-12-31 | $33.95M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-25 | $60.62M derived: sum of 2 quarters · filed 2020-02-25 | $87.50M derived: sum of 3 quarters · filed 2020-02-25 | $109.75M 10-K · filed 2020-02-25 | ||||
| 2017-09-30 | $26.68M 10-Q · filed 2018-10-30 | $53.55M derived: sum of 2 quarters · filed 2018-10-30 | $75.80M 10-Q · filed 2018-10-30 | $130.67M derived: sum of 4 quarters · filed 2019-02-22 | ||||
| 2017-06-30 | $26.87M 10-Q · filed 2018-08-02 | $49.13M 10-Q · filed 2018-08-02 | $104.00M derived: sum of 3 quarters · filed 2019-02-22 | $127.43M derived: sum of 4 quarters · filed 2019-02-22 | ||||
| 2017-03-31 | $22.25M 10-Q · filed 2018-05-02 | $77.12M derived: sum of 2 quarters · filed 2019-02-22 | $100.56M derived: sum of 3 quarters · filed 2019-02-22 | $124.43M derived: sum of 4 quarters · filed 2019-02-22 | ||||
| 2016-12-31 | $54.87M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-22 | $78.30M derived: sum of 2 quarters · filed 2019-02-22 | $102.17M derived: sum of 3 quarters · filed 2019-02-22 | $122.72M 10-K · filed 2019-02-22 | ||||
| 2016-09-30 | $23.43M 10-Q · filed 2017-11-02 | $47.30M derived: sum of 2 quarters · filed 2017-11-02 | $67.85M 10-Q · filed 2017-11-02 | $87.50M derived: sum of 4 quarters · filed 2018-02-23 | ||||
| 2016-06-30 | $23.87M 10-Q · filed 2017-08-03 | $44.42M 10-Q · filed 2017-08-03 | $64.06M derived: sum of 3 quarters · filed 2018-02-23 | $83.28M derived: sum of 4 quarters · filed 2018-02-23 | ||||
| 2016-03-31 | $20.55M 10-Q · filed 2017-05-03 | $40.19M derived: sum of 2 quarters · filed 2018-02-23 | $59.41M derived: sum of 3 quarters · filed 2018-02-23 | $77.66M derived: sum of 4 quarters · filed 2018-02-23 | ||||
| 2015-12-31 | $19.65M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-23 | $38.87M derived: sum of 2 quarters · filed 2018-02-23 | $57.11M derived: sum of 3 quarters · filed 2018-02-23 | $74.28M 10-K · filed 2018-02-23 | ||||
| 2015-09-30 | $19.22M 10-Q · filed 2016-11-03 | $37.47M derived: sum of 2 quarters · filed 2016-11-03 | $54.63M 10-Q · filed 2016-11-03 | $69.43M derived: sum of 4 quarters · filed 2017-02-23 | ||||
| 2015-06-30 | $18.25M 10-Q · filed 2016-08-04 | $35.41M 10-Q · filed 2016-08-04 | $50.21M derived: sum of 3 quarters · filed 2017-02-23 | $65.41M derived: sum of 4 quarters · filed 2017-02-23 | ||||
| 2015-03-31 | $17.16M 10-Q · filed 2016-05-05 | $31.96M derived: sum of 2 quarters · filed 2017-02-23 | $47.16M derived: sum of 3 quarters · filed 2017-02-23 | $62.10M derived: sum of 4 quarters · filed 2017-02-23 | ||||
| 2014-12-31 | $14.80M derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-23 | $30.00M derived: sum of 2 quarters · filed 2017-02-23 | $44.94M derived: sum of 3 quarters · filed 2017-02-23 | $56.29M 10-K · filed 2017-02-23 | ||||
| 2014-09-30 | $15.20M 10-Q · filed 2015-11-06 | $30.14M derived: sum of 2 quarters · filed 2015-11-06 | $41.49M 10-Q · filed 2015-11-06 | $51.12M derived: sum of 4 quarters · filed 2016-02-25 | ||||
| 2014-06-30 | $14.94M 10-Q · filed 2015-08-06 | $26.29M 10-Q · filed 2015-08-06 | $35.92M derived: sum of 3 quarters · filed 2016-02-25 | $48.01M derived: sum of 4 quarters · filed 2016-02-25 | ||||
| 2014-03-31 | $11.35M 10-Q · filed 2015-05-07 | $20.98M derived: sum of 2 quarters · filed 2016-02-25 | $33.07M derived: sum of 3 quarters · filed 2016-02-25 | $45.30M derived: sum of 4 quarters · filed 2016-02-25 | ||||
| 2013-12-31 | $9.63M derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-25 | $21.72M derived: sum of 2 quarters · filed 2016-02-25 | $33.95M derived: sum of 3 quarters · filed 2016-02-25 | $44.28M 10-K · filed 2016-02-25 | ||||
| 2013-09-30 | $12.10M 10-Q · filed 2014-11-06 | $24.32M derived: sum of 2 quarters · filed 2014-11-06 | $34.65M 10-Q · filed 2014-11-06 | $46.24M derived: sum of 4 quarters · filed 2015-02-27 | ||||
| 2013-06-30 | $12.22M 10-Q · filed 2014-08-06 | $22.56M 10-Q · filed 2014-08-06 | $34.15M derived: sum of 3 quarters · filed 2015-02-27 | $39.86M derived: sum of 4 quarters · filed 2015-02-27 | ||||
| 2013-03-31 | $10.33M 10-Q · filed 2014-05-08 | $21.93M derived: sum of 2 quarters · filed 2015-02-27 | $27.63M derived: sum of 3 quarters · filed 2015-02-27 | $35.38M derived: sum of 4 quarters · filed 2015-02-27 | ||||
| 2012-12-31 | $11.59M derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-27 | $17.30M derived: sum of 2 quarters · filed 2015-02-27 | $25.04M derived: sum of 3 quarters · filed 2015-02-27 | $29.78M 10-K · filed 2015-02-27 | ||||
| 2012-09-30 | $5.71M 10-Q · filed 2013-11-05 | $5.54M 10-Q · filed 2012-11-07 | $13.45M derived: sum of 2 quarters · filed 2013-11-05 | $18.19M 10-Q · filed 2013-11-05 | $17.55M 10-Q · filed 2012-11-07 | $25.41M derived: sum of 4 quarters · filed 2014-03-06 | ||
| 2012-06-30 | $7.75M 10-Q · filed 2013-08-06 | $7.53M 10-Q · filed 2012-08-07 | $12.48M 10-Q · filed 2013-08-06 | $12.01M 10-Q · filed 2012-08-07 | $19.71M derived: sum of 3 quarters · filed 2014-03-06 | $26.64M derived: sum of 4 quarters · filed 2014-03-06 | ||
| 2012-03-31 | $4.74M 10-Q · filed 2013-05-07 | $4.49M 10-Q · filed 2012-05-08 | $11.96M derived: sum of 2 quarters · filed 2014-03-06 | $18.90M derived: sum of 3 quarters · filed 2014-03-06 | $27.60M derived: sum of 4 quarters · filed 2014-03-06 | |||
| 2011-12-31 | $7.22M derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-06 | $14.16M derived: sum of 2 quarters · filed 2014-03-06 | $22.86M derived: sum of 3 quarters · filed 2014-03-06 | $28.62M 10-K · filed 2014-03-06 | $27.92M 10-K · filed 2012-03-13 | |||
| 2011-09-30 | $6.93M 10-Q · filed 2012-11-07 | $15.64M derived: sum of 2 quarters · filed 2012-11-07 | $21.40M 10-Q · filed 2012-11-07 | $23.80M derived: sum of 4 quarters · filed 2013-03-18 | ||||
| 2011-06-30 | $8.71M 10-Q · filed 2012-08-07 | $14.47M 10-Q · filed 2012-08-07 | $16.86M derived: sum of 3 quarters · filed 2013-03-18 | $17.63M derived: sum of 4 quarters · filed 2013-03-18 | ||||
| 2011-03-31 | $5.76M 10-Q · filed 2012-05-08 | $8.16M derived: sum of 2 quarters · filed 2013-03-18 | $8.93M derived: sum of 3 quarters · filed 2013-03-18 | $9.82M derived: sum of 4 quarters · filed 2013-03-18 | ||||
| 2010-12-31 | $2.40M derived: 10-K 12 month − 10-Q 9 month · filed 2013-03-18 | $3.17M derived: sum of 2 quarters · filed 2013-03-18 | $4.06M derived: sum of 3 quarters · filed 2013-03-18 | $4.70M 10-K · filed 2013-03-18 | $4.76M 10-K · filed 2012-03-13 | |||
| 2010-09-30 | $769.00K 10-Q · filed 2011-11-09 | $1.66M derived: sum of 2 quarters · filed 2011-11-09 | $2.30M 10-Q · filed 2011-11-09 | |||||
| 2010-06-30 | $893.00K 10-Q/A · filed 2011-08-08 | $1.53M 10-Q/A · filed 2011-08-08 | ||||||
| 2009-12-31 | $9.21M 10-K · filed 2012-03-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |